Thursday, March 30, 2023 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

SAN FRANCISCO - Impax Laboratories propped up its stock price with false and misleading statements about its Rytary drug, and the share price dropped from $20 to $14.80 when the truth came out, a shareholder claims in a federal class action.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.